

Impact of Pacemakers and Implantable Cardioverter Defibrillators on the Psychosocial Functioning of Paediatric Patients

Original Article

Cite this article: Bozat AD, Akgül S, Ertugrul İ, and Karagoz T (2021) Impact of Pacemakers and Implantable Cardioverter Defibrillators on the Psychosocial Functioning of Paediatric Patients. *Cardiology in the Young* **31**: 71–76. doi: [10.1017/S1047951120003388](https://doi.org/10.1017/S1047951120003388)


Received: 21 July 2020
Accepted: 16 September 2020
First published online: 21 October 2020

Keywords:

Quality of life; pacemaker; resilience; psychosocial functioning; ICD

Author for correspondence:

Ali Dinc Bozat, Department of Pediatrics, Hacettepe University, Ankara, Turkey.
Tel: +905339347308; Fax: +903123118226.
E-mail: alidincbozat@hotmail.com

Ali Dinc Bozat¹ , Sinem Akgül², İlker Ertugrul³ and Tevfik Karagoz³

¹Department of Pediatrics, Hacettepe University, Ankara, Turkey; ²Division of Adolescent Medicine, Department of Pediatrics, Hacettepe University, Ankara, Turkey and ³Division of Pediatric Cardiology, Department of Pediatrics, Hacettepe University, Ankara, Turkey

Abstract

Although implanted cardiac devices improve patients' physical health, long-term psychosocial effects especially in the paediatric population are still unknown. The aim of this study was to evaluate the psychosocial effects of cardiac devices in a paediatric population. Pediatric Quality of Life Questionnaire (PedsQoL) was used to evaluate life quality, Connor–Davidson Resilience Scale was used to evaluate resilience and Brief Symptom Inventory was used to evaluate psychiatric symptoms in a paediatric population with cardiac devices. Seventy-one patients were enrolled in the study. Fifty of them (70.5%) had a cardiac pacemaker and 21 of them (29.5%) had implantable cardioverter defibrillator. When compared to the control group both implantable cardioverter defibrillator and pacemaker using patients had lower quality of life (79.5 ± 12.4 versus 86.7 ± 12.1 , $p = 0.001$) but no difference was observed in resilience and psychological pathologies. Age, gender, family size, and education level had no effect on quality of life. Implantable cardioverter defibrillator bearing patients had higher levels of anxiety than pacemaker patients (0.58 versus 0.30 $p = 0.045$), and implantable cardioverter defibrillator patients who had received shock in the last year had higher levels of somatisation than the group that did not receive device shock (0.17 versus 0.44 $p = 0.022$). In conclusion study showed that cardiac devices have negative effects on the psychosocial health of children. Cardiologist working with these patients should be aware of these pathologies and monitor not only physical health but also psychosocial health too.

Implanted cardiac devices decrease cardiac symptoms, improve tolerance to exercise, and lengthen patients' lives and but despite great advancements in cardiac device technology, long-term consequences of carrying a device especially in the paediatric population remain unknown. As there are fewer paediatric patients than adults with cardiac devices, the literature concerning the psychosocial effects of the device are limited and a majority of the literature has been conducted in the adult population. But differences in the underlying cardiac disease, patient size, the psychosocial aspects of adolescence differentiate paediatric device patients from adults and results from adult studies should not be generalised to the paediatric population.

Implanted devices may be a pacemaker or an implantable cardioverter defibrillator. Both devices have the same physical specifications. A battery is placed subcutaneously or submuscular either into the abdomen or left axilla and is connected to the heart with one or more electrodes. These electrodes carry the electric impulse to the heart.¹ While pacemaker's deliver impulses continuously to establish a proper cardiac rhythm, implantable cardioverter defibrillator's monitor the rhythm of the heart and when it senses an abnormal rhythm it delivers high voltage energy to heart in order to abolish arrhythmia. Underlying diseases for device implantation vary in large spectrum. These patients may have an implanted device due to postoperative complete atrioventricular block after congenital heart surgery or a high-risk channelopathy for primary or secondary prevention of sudden death.² In addition to the implantation procedure, interventions related with the underlying disease is another burden such as expectation of high voltage delivery (shock), changes in life style, avoidance of injury to the device, and regular follow ups and hospital visits that interfere daily activities.^{3–5}

These chronic conditions may lead to mental health problems and disturb quality of life. For the adult population with implantable cardioverter defibrillators or pacemakers, anxiety and depression are well studied pathologies. In a systemic review anxiety and/or depression was reported as 20% in the pacemaker population.⁶ In another study, 22% of all patients with implantable cardioverter defibrillators had at least one psychological problem with adjustment disorder and depression being the most common.⁷ Studies have also shown quality of life to be disturbed in both implantable cardioverter defibrillator and pacemaker population, especially in physical quality of life^{8,9} but in particular in those receiving shock.¹⁰

There are very few studies in the paediatric population looking at the psychosocial effects of both pacemakers and implantable cardioverter defibrillators and the results are conflicting. One study showed that children with implantable cardioverter defibrillators have the same levels of anxiety and depression as the healthy population. However, in these patients physical and social functions were found to be worse when compared to the healthy population.¹¹ Whereas Webster et al reported that patients with implantable cardioverter defibrillators have a higher risk of psychological disease than patients with pacemakers and higher levels of anxiety than the normal population. They also stated that there were no significant changes in depression between those with devices or the healthy controls.¹²

Resilience in these patients remain unknown. Resilience is the ability to cope with stress.¹³ A resilient person can continue their normal life after a negative situation and have a positive outcome after this. However, establishing resilience can differ within different situations and populations. Higher resilience can have a positive effect on the patient's life. Because of this, many studies have been conducted to identify levels of resilience in patients with chronic illnesses and ways to establish it. In most of the studies higher levels of resilience have been shown.^{14–17}

The aim of the study was to evaluate quality of life, the presence of psychological pathologies and resilience levels of implantable cardioverter defibrillator and pacemaker bearing children.

Method

A total of 71 patients with an implanted implantable cardioverter defibrillator or pacemaker and a control group consisting of 62 healthy children matched for age and sex were included in the study. Demographics and information concerning the implanted device and the duration of the device, number of procedures and age at implantation were obtained from hospital records. In addition to this data patients school attendance, family size and family education were asked. Pediatric Quality of Life Scale, Connor–Davidson Resilience Scale, Brief Symptom Inventory were applied to parents and patients.

Pediatric Quality of Life Scale is a questionnaire developed by Warni et al in 1999. It was established to evaluate life quality. It also gives additionally information about physical and psychosocial health, emotional, school, and social functioning. Number and type of question depends on the patients age. Questionnaires for four age groups (2–4, 5–7, 8–12, 13–18) have been established. Between ages 2–4 questions can be only answered by parents, whereas for the other age groups it can be completed by either children or the patient.^{18,19} The Turkish translation and reliability and validity studies were conducted by Memik et al and Uneri et al.^{20–22}

Connor–Davidson Resilience Scale was developed by Connor and Davidson in 2003 to evaluate resilience in children. It consists of 25 questions each have 5 different answers which has a different point of 0–5. Higher points mean higher resilience.²³ Turkish translation and reliability and validity studies were conducted by Kararmak et al.²⁴

Brief Symptom Inventory is a simplified version of the Symptom Check List-90. It was developed by Derogatis et al in 1993. From 90 questions, 53 of them were selected during this process. It was shown as a reliable tool to detect psychological problems associated with various medical problems. Answers vary from never to always. Participants were asked to answer these questions according to their last week. Analysis is made in the areas of anger, somatisation, anxiety, depression, and negative sense of

self.²⁵ The Turkish translation and reliability and validity studies were conducted by Sahin et al.²⁶

While all three questionnaires were given to participants between ages of 13–18 years and completed by the adolescent, only Pediatric Quality of Life Scale was given to those between the ages of 2–13 years and were completed by the parents. Informed consent was obtained from all participants. During the application of the questionnaires a member of the research group was present. The study was approved by the institutional review board at Hacettepe University (GO 17/477-21).

Statistical analysis was made using SPSS 20 software. Variability of the results was assessed with Kolmogorov–Smirnov test. Numeric variables with a normal distribution were shown as mean and standard variation while numeric variables without a normal distribution were shown as min–max. To evaluate variables associated with different risk groups, T tests and Mann–Whitney U tests were used. In risk categories with three variables, Analysis of Variance and Kruskal–Wallis H tests were used. To evaluate categorical data, Chi-Square Tests were used.

Results

A total of 71 patients (36 male) were enrolled in the study group. There was almost equal distribution between ages of 5–12 years and 13–18 years (31 versus 30), and 10 of these patients were between 2–4 years. Mean age was 11.08 ± 4.86 (2–18). A control group was established with 62 healthy children whose age and sex was similar to the study group (Table 1).

The implanted device was an implantable cardioverter defibrillator in 21 patients (29.5%) and pacemaker in 50 patients (70.5%). Thirty-three of these devices were implanted via the transvenous route and 38 of them were implanted with surgical epicardial route. Eight of the 21 patients who had an implantable cardioverter defibrillator received at least one shock therapy during the last year. Mean number of shocks in the last year was 21.86 ± 28.41 (0–73). Indications of device implantation are shown in Table 2.

Fifty-two patients (73%) attended school. Only 12.6% of them had a sibling who had a heart disease ($n = 9$) while 4 of them had additional device bearing relatives.

When patients were evaluated with the Pediatric Quality of Life Scale, physical health, psychosocial health, and emotional functioning points were found to be significantly lower than that of the control group (Table 3). Factors effecting quality of life were also studied, these groups were compared in respect of age, gender, health history, family size, and educational level (both parents and family). There was no risk factor leading to lower levels of life quality except carrying the device. Additionally, type of device and implantation had no effect on quality of life (Table 4).

Nine patients had a sibling who had an implanted device (implantable cardioverter defibrillator or pacemaker), their quality of life measurements and social functioning points were significantly lower than patients who had no sibling with a device (Scale total point 71.2 ± 15.4 versus 80.6 ± 11.6 $p = 0.032$) (Social functioning point 76.1 ± 23.7 versus 91.1 ± 10.3 $p = 0.001$).

Using the Connor–Davidson Resilience Scale there was no difference when study and control group were compared in respect of resilience. Additionally, no difference in resilience was found between type of device (Tables 4 and 5).

According to the Brief Symptom Inventory evaluation, the number of patients with symptoms of anxiety, depression, negative sense of self, somatisation, and anger were not different from the control group (Table 5).

Table 1. Distribution of age and sex.

Demographics	Study n = 71	Control n = 62	p
Sex			0.651
Male	36 (50.7)	29 (46.8)	
Female	35 (49.3)	33 (53.2)	
Age			0.494
2–4	10 (14.1)	11 (17.7)	
5–12	31 (43.7)	31 (50.0)	
13–18	30 (42.3)	20 (32.3)	

Table 2. Implantation indications for the devices.

Number	
PM implantation indications	
Postoperative complete AV Block	35
Congenital complete AV Block	11
Sick Sinus Syndrome	4
Implantable cardioverter defibrillator implantation indications	
Long QT Syndrome	11
Dilated Cardiomyopathy	1
Hypertrophic Cardiomyopathy	2
History of Cardiac Arrest	4
Ventricular Tachycardia	3

Table 3. PedQoL results.

Scales	Study n = 71	Control n = 62	p
PHTP	77.1 ± 17.6	87.3 ± 13.3	<0.001*
PSHTP	80.4 ± 13.3	86.6 ± 13.7	0.009*
EFP	74.4 ± 19.5	81.6 ± 16.1	0.022*
SFP	89.2 ± 13.5	93.4 ± 14.3	0.083
SCHP	76.4 ± 18.5	83.9 ± 19.9	0.037*
STP	79.5 ± 12.4	86.7 ± 12.1	0.001*

EFP: Emotional functioning total point, PHTP: Physical health total point, PSHTP: Psychosocial health total point, SCHP: School functioning total point, SFP: Social functioning total point, STP: Scale total point

We found statistically different levels of anxiety between types of devices. Implantable cardioverter defibrillator patients had a higher mean anxiety score of 0.58 (0.15–2.38) when compared to pacemaker patients who had a mean anxiety score of 0.30 (0–1.38) ($p = 0.045$). In patients bearing implantable cardioverter defibrillator, 38% of them ($n = 8$) had at least one shock treatment in the last year. The mean number of shocks received in the last year was 21.86 ± 28.41 (0–73). The Brief Symptom Inventory scores of patients who received shock was compared with those that did not and we found that the somatisation subscale was significantly higher in the shock population (0.17 versus 0.44 $p = 0.022$).

Discussion

Intracardiac devices are lifesaving therapeutic devices and in spite of their technical advances long-term psychosocial affects in children are less known. The aim of this study was to evaluate life quality, resilience, and psychiatric pathologies in intracardiac device bearing children. The main result of our study was that lower quality of life was observed in device bearing patients irrespective of the type of device and higher levels of anxiety were seen in those with implantable cardiac devices.

The quality of life studies in adults with pacemakers are conflicting. While some studies have shown improvement, some studies have shown deterioration. A study by Barros et al in adults showed that life quality deteriorates after the implantation but emotional and social quality improves.⁹ As we expected, patients in this study had a lower life quality in terms of physical, social, school functioning, and emotional functioning validating concerns with regard to this patient population. Similar to our results, a systemic review looking at quality of life in paediatric-specific intracardiac device bearers also demonstrated lower quality of life compared with healthy controls.²⁷

Research in other chronic cardiac diseases also show the same effect on quality of life. Wilmot et al showed negative effects on emotional and social areas in patients with heart failure.²⁸ A study by Bratt et al stated that CHD patients who lived through childhood and moved to adult life have a lower quality of life especially in emotional area. They also stated that mild disease means lower decline in quality of life.²⁹

Not surprisingly, the quality of life was worse in patients who also had a sibling with a device. This is a comprehensible result as the burden of having more than one child requiring an intracardiac device increases the psychosocial load on the family placing this vulnerable population at greater risk for lower quality of life.

When comparing devices in the present study implantable cardioverter defibrillator bearing patients had higher levels of anxiety than patients bearing pacemakers. Implantable cardioverter defibrillator is a device that transmits shock to the heart when it detects an arrhythmia. This unpredictable shock is painful. So, the constant fear of receiving a shock is common in patients. The systemic review by Pyngottu et al similarly reported pacemaker bearers to have no significant difference with respect to anxiety and depression symptoms, while implantable cardioverter defibrillator patients showed more signs of anxiety than depression.²⁷ Kikkenborg Berg et al and Qintar et al showed that implantable cardioverter defibrillator patients have higher levels of anxiety in adult population.^{30,31} These studies also showed that if the patient had received a device shock recently their anxiety level was higher.

We also found higher levels of somatisation with higher numbers of device shock, which to the best of our knowledge was not previously shown. Somatisation is the tendency to experience psychological distress in the form of somatic symptoms. These patients tend to seek medical help for these somatic symptoms. Higher somatisation rates mean higher rates of somatic symptoms due to psychological distress. These unexplained medical symptoms will lead to disability in patients, excess use of medical services, and frustration in both patients and physicians.³² Again, this result can be expected as studies looking at somatisation in children have shown that in many cases a physical illness or disorder precipitates the somatising disorder.³³ Higher levels of somatisation may be due to the constant fear of receiving device shock, as experiencing this

Table 4. Scale results between devices and implantation method

Scales	Device		p	Implantation Method		p
	ICD n = 21	PM n = 50		Epicardial n = 38	Endocardial n = 33	
PedsQoL						
PHTP	72.1 ± 13.4	79.2 ± 18.8	0.118	78.7 ± 16.5	75.3 ± 18.8	0.419
PSHTP	79.8 ± 11.9	80.6 ± 13.9	0.817	80.7 ± 14.7	80.0 ± 11.7	0.843
EFP	76.7 ± 10.6	80.6 ± 13.0	0.220	79.8 ± 13.7	79.1 ± 11.0	0.832
SFP	74.8 ± 19.7	74.2 ± 19.6	0.899	72.2 ± 20.1	76.8 ± 18.7	0.326
SCHP	86.4 ± 13.0	90.4 ± 13.7	0.264	90.0 ± 13.2	88.3 ± 14.1	0.600
STP	80.0 ± 14.7	74.8 ± 20.0	0.314	76.8 ± 20.9	76.1 ± 16.4	0.886
BSI						
Anxiety	0.58 (0.15–2.38)	0.30 (0–1.38)	0.045*	0.38 (0–1.38)	0.53 (0–2.38)	0.641
Depression	0.50 (0.11–1.30)	0.58 (0–1.25)	0.775	0.50 (0–1.08)	0.58 (0.08–1.3)	0.582
Negative Sense of Self	0.41 (0.08–1.58)	0.5 (0–1.33)	0.683	0.50 (0–1.25)	0.41 (0.16–1.58)	0.553
Somatisation	0.44 (0.11–1.33)	0.22 (0–1.77)	0.067	0.33 (0–0.77)	0.44 (0–1.77)	0.171
Anger	0.71 (0.14–2.42)	1.00 (0–3.14)	0.595	1.14 (0.16–3.14)	0.71 (0–2.42)	0.287
RCI	0.58 (0.17–1.65)	0.56 (0.05–1.20)	0.412	0.56 (0.05–1.18)	0.58 (0.07–1.65)	0.553
CD-RISC	50 (11–91)	68.5 (32–97)	0.432	68.5 (39–91)	47.5 (11–97)	0.262

BSI: Brief symptom inventory, CD-RISC: Connor–Davidson Resilience Scale, EFP: emotional functioning total point, ICD: Implantable Cardioverter Defibrillator, PedsQoL: Pediatric Quality of Life Scale, PHTP: Physical health total point, PM: Pacemaker, PSHTP: Psychosocial health total point, SCHP: School functioning total point, SFP: Social functioning total point, STP: Scale total point, RCI: BSI total point

Table 5 BSI and CD-RISC results

Scales	Study n = 30	Control n = 20	p
CD-RISC	59.5 (11–97)	76.5 (26–94)	0.118
BSI			
Anxiety	0.5 (0–2.4)	0.6 (0.2–2.7)	0.405
Depression	0.5 (0–1.3)	0.4 (0.1–2.7)	0.889
Negative Sense of Self	0.5 (0–1.6)	0.5 (0.1–2.9)	0.662
Somatisation	0.3 (0–1.8)	0.4 (0–1.8)	0.556
Anger	0.8 (0–3.1)	0.6 (0–2.1)	0.393
RCI	0.6 (0.1–1.7)	0.5 (0.1–2.2)	0.921
Psychological Pathology			
Negative	25 (83.3)	16 (80.0)	0.997
Positive	5 (16.7)	4 (20)	

BSI: Brief symptom inventory, CD-RISC: Connor–Davidson Resilience Scale, RCI: BSI total point

painful experience may lead to psychological distress which in turn may trigger somatisation.

We found no difference in psychological pathologies between the study and control group using Brief Symptom Inventory, which was applied to the adolescent population only. There are few studies in patients with cardiac devices or arrhythmias concerning psychological pathologies. The most commonly studied pathology has been Long QT Syndrome. A majority of studies have shown increased levels of anxiety and anger.^{34–36} Similarly, a study evaluating psychosocial factors in children with implantable

cardioverter defibrillators also showed that anxiety and depression were not increased. In their study DeMaso argued that these low scores could reflect a sense of security leading to lower levels of depression and anxiety after receiving the device.¹¹

To the best of our knowledge, this was the first study to look at resilience in children and adolescents with a cardiac device. Although many studies have shown higher resilience in children with chronic diseases,^{37–39} we found no difference in resilience compared to the healthy controls. A study looking at resilience in adolescents with CHD compared resilience in a group with mild versus severe disease. They showed that the higher the severity of CHD, the lower the level of resilience.⁴⁰

Our patient population had a wide range a device implications ranging from mild to severe cardiac pathologies. Differences in disease severity may have an effect on resilience. Unfortunately, secondary to inadequate sample size, we were unable to make comparisons of resilience between patients with different implications for cardiac devices.

This study has several strengths, primarily it evaluated a cohort of both implantable cardioverter defibrillator and pacemaker bearing children and adds to the paucity of literature regarding this subject. The sample was comprised of children and adolescents with a variety of device indications and therefore more likely to accurately capture a wider range of this vulnerable patient population. However, the study also has certain limitations. Our main limitation was the small number of participants in the study, which may have limited our power to detect differences in levels of depression and anxiety that may have been clinically relevant, as well as limiting generalisability. Although the assessment tools used in this study are well validated and widely used, they were all self-report, which can introduce biases. Furthermore, measures were not collected at the same time after device implantation for

each case, as the amount of time that passed after the device was inserted was not standard this may have affected the results. Finally, data was only collected once, evaluating the patient before and after device implantation may show a difference in device-related psychosocial functioning.

In conclusion, our study shows that quality of life is significantly affected in patients with cardiac devices especially in the areas of physical, psychosocial health, emotional, and school functioning. Additionally, patients with implantable cardioverter defibrillators have higher levels of anxiety and higher levels of somatisation with higher numbers of device shock. These findings support the notion that patients with cardiac devices should receive psychosocial support and particular attention should be given to implantable cardioverter defibrillator bearing children and those families when more than one child is affected. Cardiologists working with implantable cardioverter defibrillator bearing children should also be aware of higher levels of somatisation in these patients.

Acknowledgements. None.

Financial support. This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

Conflicts of interest. None.

Ethical standards. The procedure conformed to the guidelines of the local ethical committee. Informed consent was obtained from the parents.

References

- Park MK. Cardiac pacemakers and implantable cardioverter-defibrillators in children. In: Park MK, Salamat M (eds). *Park's Pediatric Cardiology for Practitioners*. Elsevier, Philadelphia, PA, 2014: 440–448.
- Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. *Circulation* 2008; 117: e350–e408. doi: [10.1161/circulationaha.108.189742](https://doi.org/10.1161/circulationaha.108.189742)
- Wang Q, Hay M, Clarke D, Menahem S. The prevalence and predictors of anxiety and depression in adolescents with heart disease. *J Pediatr* 2012; 161: 943–946. doi: [10.1016/j.jpeds.2012.04.010](https://doi.org/10.1016/j.jpeds.2012.04.010)
- Kasmi L, Calderon J, Montreuil M, et al. Neurocognitive and psychological outcomes in adults with dextro-transposition of the great arteries corrected by the arterial switch operation. *Ann Thorac Surg* 2018; 105: 830–836. doi: [10.1016/j.athoracsur.2017.06.055](https://doi.org/10.1016/j.athoracsur.2017.06.055)
- Alkan F, Sertcelik T, Yalin Sapmaz S, Eser E, Coskun S. Responses of mothers of children with CHD: quality of life, anxiety and depression, parental attitudes, family functionality. *Cardiol Young* 2017; 27: 1748–1754. doi: [10.1017/s1047951117001184](https://doi.org/10.1017/s1047951117001184)
- Magyar-Russell G, Thombs BD, Cai JX, et al. The prevalence of anxiety and depression in adults with implantable cardioverter defibrillators: a systematic review. *J Psychosomat Res* 2011; 71: 223–231. doi: [10.1016/j.jpsychores.2011.02.014](https://doi.org/10.1016/j.jpsychores.2011.02.014)
- Aydemir O, Ozmen E, Kuey L, et al. Psychiatric morbidity and depressive symptomatology in patients with permanent pacemakers. *Pacing Clin Electrophysiol* 1997; 20: 1628–1632.
- Mlynarska A, Mlynarski R, Golba KS. Influence of frailty on the quality of life patients qualified for pacemaker implantation. *J Clin Nurs* 2018; 27: 555–560. doi: [10.1111/jocn.13897](https://doi.org/10.1111/jocn.13897)
- Barros RT, Carvalho SM, Silva MA, Borges JB. Evaluation of patients' quality of life aspects after cardiac pacemaker implantation. *Rev Bras Cir Cardiov* 2014; 29: 37–44.
- Rhodes AC, Murray B, Tichnell C, James CA, Calkins H, Sears SF. Quality of life metrics in arrhythmogenic right ventricular cardiomyopathy patients: the impact of age, shock and sex. *Int J Cardiol* 2017; 248: 216–220. doi: [10.1016/j.ijcard.2017.08.026](https://doi.org/10.1016/j.ijcard.2017.08.026)
- DeMaso DR, Lauretti A, Spieth L, et al. Psychosocial factors and quality of life in children and adolescents with implantable cardioverter-defibrillators. *Am J Cardiol* 2004; 93: 582–587. doi: [10.1016/j.amjcard.2003.11.022](https://doi.org/10.1016/j.amjcard.2003.11.022)
- Webster G, Panek KA, Labella M, et al. Psychiatric functioning and quality of life in young patients with cardiac rhythm devices. *Pediatrics* 2014; 133: e964–e972. doi: [10.1542/peds.2013-1394](https://doi.org/10.1542/peds.2013-1394)
- Sapienza JK, Masten AS. Understanding and promoting resilience in children and youth. *Curr Opin Psychiatry* 2011; 24: 267–273. doi: [10.1097/YCO.0b013e32834776a8](https://doi.org/10.1097/YCO.0b013e32834776a8)
- Masten AS. Resilience in children threatened by extreme adversity: frameworks for research, practice, and translational synergy. *Dev Psychopathol* 2011; 23: 493–506. doi: [10.1017/s0954579411000198](https://doi.org/10.1017/s0954579411000198)
- Masten AS. Resilience in developing systems: progress and promise as the fourth wave rises. *Dev Psychopathol* 2007; 19: 921–930. doi: [10.1017/s0954579407000442](https://doi.org/10.1017/s0954579407000442)
- Masten AS. Ordinary magic: resilience processes in development. *Am Psychol* 2001; 56: 227–238.
- Cicchetti D. Resilience under conditions of extreme stress: a multilevel perspective. *World Psychiatry* 2010; 9: 145–154.
- Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. *Med Care* 2001; 39: 800–812.
- Ravens-Sieberer U, Karow A, Barthel D, Klasen F. How to assess quality of life in child and adolescent psychiatry. *Dialogues Clin Neurosci* 2014; 16: 147–158.
- Uneri OS, Agaoglu B, Coskun A, Memik NC. Validity and reliability of Pediatric Quality of Life Inventory for 2- to 4-year-old and 5- to 7-year-old Turkish children. *Qual Life Res* 2008; 17: 307–315. doi: [10.1007/s11136-007-9303-4](https://doi.org/10.1007/s11136-007-9303-4)
- Memik NC, Ağaoglu B, Coşkun A, Üneri O, Karakaya I. Çocuklar için yaşam kalitesi ölçeğinin 13–18 yaş ergen formunun geçerlik ve güvenilirliği. *Türk Psikiyatri Dergisi* 2007; 18: 353–363.
- Memik N, Ağaoglu B, Coskun A. The validity and reliability of Pediatric Quality of Life Inventory in 8–12 years old Turkish children. *Çocuk ve Gençlik Ruh Sağlığı Dergisi* 2008; 15: 353–363.
- Connor KM, Davidson JR. Development of a new resilience scale: the Connor-Davidson Resilience Scale (CD-RISC). *Depress Anxiety* 2003; 18: 76–82. doi: [10.1002/da.10113](https://doi.org/10.1002/da.10113)
- Karairmak O. Establishing the psychometric qualities of the Connor-Davidson Resilience Scale (CD-RISC) using exploratory and confirmatory factor analysis in a trauma survivor sample. *Psychiatry Res* 2010; 179: 350–356. doi: [10.1016/j.psychres.2009.09.012](https://doi.org/10.1016/j.psychres.2009.09.012)
- Derogatis LR, Melisaratos N. The Brief Symptom Inventory: an introductory report. *Psychol Med* 1983; 13: 595–605.
- hisli sahin N, Batgün A. Kisa Semptom Envanteri: Türk gençleri için uyarlanması. *Türk Psikoloji Dergisi* 1994; 9: 44–56.
- Pyngottu A, Werner H, Lehmann P, Balmer C. Health-related quality of life and psychological adjustment of children and adolescents with pacemakers and implantable cardioverter defibrillators: a systematic review. *Pediatr Cardiol* 2019; 40: 1–16. doi: [10.1007/s00246-018-2038-x](https://doi.org/10.1007/s00246-018-2038-x)
- Wilmot I, Cephus CE, Cassidy A, Kudel I, Marino BS, Jefferies JL. Health-related quality of life in children with heart failure as perceived by children and parents. *Cardiol Young* 2016; 26: 885–893. doi: [10.1017/s1047951115001468](https://doi.org/10.1017/s1047951115001468)
- Bratt EL, Luyckx K, Goossens E, Budts W, Moons P. Patient-reported health in young people with congenital heart disease transitioning to adulthood. *J Adolesc Health* 2015; 57: 658–665. doi: [10.1016/j.jadohealth.2015.07.021](https://doi.org/10.1016/j.jadohealth.2015.07.021)
- Qintar M, George JJ, Panko M, et al. A prospective study of anxiety in ICD patients with a pilot randomized controlled trial of cognitive behavioral therapy for patients with moderate to severe anxiety. *J Interv Card Electrophysiol* 2015; 43: 65–75. doi: [10.1007/s10840-015-9990-7](https://doi.org/10.1007/s10840-015-9990-7)

31. Kikkenborg Berg S, Caspar Thygesen L, Hastrup Svendsen J, Vinggaard Christensen A, Zwisler AD. Anxiety predicts mortality in ICD patients: results from the cross-sectional national CopenHeartICD survey with register follow-up. *Pacing Clin Electrophysiol* 2014; 37: 1641–1650. doi: [10.1111/pace.12490](https://doi.org/10.1111/pace.12490)
32. Al Busaidi ZQ. The concept of somatisation: a cross-cultural perspective. *Sultan Qaboos Univ Med J* 2010; 10: 180–186.
33. Garralda ME. Somatisation in children. *J Child Psychol Psychiatry* 1996; 37: 13–33. doi: [10.1111/j.1469-7610.1996.tb01378.x](https://doi.org/10.1111/j.1469-7610.1996.tb01378.x)
34. Waddell-Smith KE, Ertresvaag KN, Li J, et al. Physical and psychological consequences of left cardiac sympathetic denervation in long-QT syndrome and catecholaminergic polymorphic ventricular tachycardia. *Circ Arrhythm Electrophysiol* 2015; 8: 1151–1158. doi: [10.1161/circep.115.003159](https://doi.org/10.1161/circep.115.003159)
35. Hintsala T, Jokela M, Elovainio M, et al. Stressful life events and depressive symptoms among symptomatic long QT syndrome patients. *J Health Psychol* 2016; 21: 505–512. doi: [10.1177/1359105314530450](https://doi.org/10.1177/1359105314530450)
36. Hamang A, Eide GE, Rokne B, Nordin K, Bjorvatn C, Øyen N. Predictors of heart-focused anxiety in patients undergoing genetic investigation and counseling of long QT syndrome or hypertrophic cardiomyopathy: a one year follow-up. *J Genet Counsel* 2012; 21: 72–84. doi: [10.1007/s10897-011-9393-6](https://doi.org/10.1007/s10897-011-9393-6)
37. Evers AW, Kraaimaat FW, Geenen R, Jacobs JW, Bijlsma JW. Stress-vulnerability factors as long-term predictors of disease activity in early rheumatoid arthritis. *J Psychosom Res* 2003; 55: 293–302.
38. DeMaso DR, Spratt EG, Vaughan BL, D'Angelo EJ, Van der Feen JR, Walsh E. Psychological functioning in children and adolescents undergoing radio-frequency catheter ablation. *Psychosomatics* 2000; 41: 134–139.
39. Noll RB, Vannatta K, Koontz K, Kalinyak K, Bukowski WM, Davies WH. Peer relationships and emotional well-being of youngsters with sickle cell disease. *Child Develop* 1996; 67: 423–436.
40. Moon JR, Song J, Huh J, et al. The relationship between parental rearing behavior, resilience, and depressive symptoms in adolescents with congenital heart disease. *Front Cardiovasc Med* 2017; 4: 55–55. doi: [10.3389/fcvm.2017.00055](https://doi.org/10.3389/fcvm.2017.00055)